382 related articles for article (PubMed ID: 19487279)
1. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
[TBL] [Abstract][Full Text] [Related]
2. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
Maréchal R; Van Laethem JL
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
[TBL] [Abstract][Full Text] [Related]
3. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
Williams TK; Costantino CL; Bildzukewicz NA; Richards NG; Rittenhouse DW; Einstein L; Cozzitorto JA; Keen JC; Dasgupta A; Gorospe M; Gonye GE; Yeo CJ; Witkiewicz AK; Brody JR
PLoS One; 2010 Nov; 5(11):e15455. PubMed ID: 21152064
[TBL] [Abstract][Full Text] [Related]
4. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
[TBL] [Abstract][Full Text] [Related]
5. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
[TBL] [Abstract][Full Text] [Related]
6. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
[TBL] [Abstract][Full Text] [Related]
7. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
[TBL] [Abstract][Full Text] [Related]
8. HuR's role in gemcitabine efficacy: an exception or opportunity?
Brody JR; Gonye GE
Wiley Interdiscip Rev RNA; 2011; 2(3):435-44. PubMed ID: 21957028
[TBL] [Abstract][Full Text] [Related]
9. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
Zhou H; Telonis AG; Jing Y; Xia NL; Biederman L; Jimbo M; Blanco F; Londin E; Brody JR; Rigoutsos I
Cell Death Dis; 2016 Jul; 7(7):e2294. PubMed ID: 27415424
[TBL] [Abstract][Full Text] [Related]
10. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
[TBL] [Abstract][Full Text] [Related]
11. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
13. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
14. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Xiong J; Altaf K; Ke N; Wang Y; Tang J; Tan C; Li A; Zhang H; He D; Liu X
Medicine (Baltimore); 2016 Mar; 95(10):e2936. PubMed ID: 26962792
[TBL] [Abstract][Full Text] [Related]
15. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
Dash S; Ueda T; Komuro A; Honda M; Sugisawa R; Okada H
Cell Death Dis; 2024 Feb; 15(2):131. PubMed ID: 38346958
[TBL] [Abstract][Full Text] [Related]
16. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
Tatarian T; Jiang W; Leiby BE; Grigoli A; Jimbo M; Dabbish N; Neoptolemos JP; Greenhalf W; Costello E; Ghaneh P; Halloran C; Palmer D; Buchler M; Yeo CJ; Winter JM; Brody JR
Ann Surg; 2018 Feb; 267(2):364-369. PubMed ID: 27893535
[TBL] [Abstract][Full Text] [Related]
18. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
Lal S; Burkhart RA; Beeharry N; Bhattacharjee V; Londin ER; Cozzitorto JA; Romeo C; Jimbo M; Norris ZA; Yeo CJ; Sawicki JA; Winter JM; Rigoutsos I; Yen TJ; Brody JR
Cancer Res; 2014 Feb; 74(4):1128-40. PubMed ID: 24536047
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
[TBL] [Abstract][Full Text] [Related]
20. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]